Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 314

1.

Trabectedin reveals a strategy of immunomodulation in chronic lymphocytic leukemia.

Banerjee P, Zhang R, Ivan C, Galletti G, Clise-Dwyer K, Barbaglio F, Scarfò L, Aracil M, Klein C, Wierda W, Plunkett W, Caligaris Cappio F, Gandhi V, Keating MJ, Bertilaccio MTS.

Cancer Immunol Res. 2019 Sep 17. pii: canimm.0152.2019. doi: 10.1158/2326-6066.CIR-19-0152. [Epub ahead of print]

PMID:
31530560
2.

CNDAC-induced DNA double strand breaks cause aberrant mitosis prior to cell death.

Liu X, Jiang Y, Takata KI, Nowak B, Liu C, Wood RD, Hittelman WN, Plunkett W.

Mol Cancer Ther. 2019 Sep 9. pii: molcanther.1380.2018. doi: 10.1158/1535-7163.MCT-18-1380. [Epub ahead of print]

PMID:
31501277
3.

Oncogenic KRAS Reduces Expression of FGF21 in Acinar Cells to Promote Pancreatic Tumorigenesis in Mice on a High-Fat Diet.

Luo Y, Yang Y, Liu M, Wang D, Wang F, Bi Y, Ji J, Li S, Liu Y, Chen R, Huang H, Wang X, Swidnicka-Siergiejko AK, Janowitz T, Beyaz S, Wang G, Xu S, Bialkowska AB, Luo CK, Pin CL, Liang G, Lu X, Wu M, Shroyer KR, Wolff RA, Plunkett W, Ji B, Li Z, Li E, Li X, Yang VW, Logsdon CD, Abbruzzese JL, Lu W.

Gastroenterology. 2019 Jul 25. pii: S0016-5085(19)41127-X. doi: 10.1053/j.gastro.2019.07.030. [Epub ahead of print]

PMID:
31352001
4.

Ibrutinib and Venetoclax for First-Line Treatment of CLL.

Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W.

N Engl J Med. 2019 May 30;380(22):2095-2103. doi: 10.1056/NEJMoa1900574.

PMID:
31141631
5.

HSP90 inhibition depletes DNA repair proteins to sensitize acute myelogenous leukemia to nucleoside analog chemotherapeutics.

Lai TH, Mitchell S, Wu PJ, Orwick S, Liu C, Ravikrishnan J, Woyach J, Mims A, Plunkett W, Puduvalli VK, Byrd JC, Lapalombella R, Sampath D.

Leuk Lymphoma. 2019 Sep;60(9):2308-2311. doi: 10.1080/10428194.2019.1571197. Epub 2019 Feb 18. No abstract available.

PMID:
30773117
6.

Creating novel translation inhibitors to target pro-survival proteins in chronic lymphocytic leukemia.

Chen R, Zhu M, Chaudhari RR, Robles O, Chen Y, Skillern W, Qin Q, Wierda WG, Zhang S, Hull KG, Romo D, Plunkett W.

Leukemia. 2019 Jul;33(7):1663-1674. doi: 10.1038/s41375-018-0364-x. Epub 2019 Jan 30.

PMID:
30700841
7.

Phase 1/2 study of DFP-10917 administered by continuous intravenous infusion in patients with recurrent or refractory acute myeloid leukemia.

Kantarjian HM, Jabbour EJ, Garcia-Manero G, Kadia TM, DiNardo CD, Daver NG, Borthakur G, Jain N, Waukau JB, Kwari MI, Ravandi F, Anderson BD, Iizuka K, Jin C, Zhang C, Plunkett WK.

Cancer. 2019 May 15;125(10):1665-1673. doi: 10.1002/cncr.31923. Epub 2019 Jan 22.

PMID:
30668890
8.

Comprehensive Ara-C SNP score predicts leukemic cell intracellular ara-CTP levels in pediatric acute myeloid leukemia patients.

Elsayed AH, Cao X, Crews KR, Gandhi V, Plunkett W, Rubnitz JE, Ribeiro RC, Pounds SB, Lamba JK.

Pharmacogenomics. 2018 Sep 1;19(14):1101-1110. doi: 10.2217/pgs-2018-0086. Epub 2018 Aug 8.

9.

Targeting BRCA1/2 deficient ovarian cancer with CNDAC-based drug combinations.

Liu X, Jiang Y, Nowak B, Qiang B, Cheng N, Chen Y, Plunkett W.

Cancer Chemother Pharmacol. 2018 Feb;81(2):255-267. doi: 10.1007/s00280-017-3483-6. Epub 2017 Nov 30.

10.

TDP1 is Critical for the Repair of DNA Breaks Induced by Sapacitabine, a Nucleoside also Targeting ATM- and BRCA-Deficient Tumors.

Al Abo M, Sasanuma H, Liu X, Rajapakse VN, Huang SY, Kiselev E, Takeda S, Plunkett W, Pommier Y.

Mol Cancer Ther. 2017 Nov;16(11):2543-2551. doi: 10.1158/1535-7163.MCT-17-0110. Epub 2017 Aug 11.

11.

A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia.

Short NJ, Kantarjian H, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W, Gandhi V, Sasaki K, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, Kadia TM, Wierda WG, DiNardo CD, Brandt M, O'Brien SM, Cortes JE, Jabbour E.

Leuk Lymphoma. 2018 Apr;59(4):813-820. doi: 10.1080/10428194.2017.1349907. Epub 2017 Jul 18.

12.

A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia.

Jabbour E, Short NJ, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W, Gandhi V, Sasaki K, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, Kadia TM, Wierda WG, DiNardo CD, Brandt M, O'Brien SM, Cortes JE, Kantarjian H.

Cancer. 2017 Nov 15;123(22):4430-4439. doi: 10.1002/cncr.30883. Epub 2017 Jul 14.

13.

Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers.

Van Roosbroeck K, Fanini F, Setoyama T, Ivan C, Rodriguez-Aguayo C, Fuentes-Mattei E, Xiao L, Vannini I, Redis RS, D'Abundo L, Zhang X, Nicoloso MS, Rossi S, Gonzalez-Villasana V, Rupaimoole R, Ferracin M, Morabito F, Neri A, Ruvolo PP, Ruvolo VR, Pecot CV, Amadori D, Abruzzo L, Calin S, Wang X, You MJ, Ferrajoli A, Orlowski R, Plunkett W, Lichtenberg TM, Davuluri RV, Berindan-Neagoe I, Negrini M, Wistuba II, Kantarjian HM, Sood AK, Lopez-Berestein G, Keating MJ, Fabbri M, Calin GA.

Clin Cancer Res. 2017 Jun 1;23(11):2891-2904. doi: 10.1158/1078-0432.CCR-16-1025. Epub 2016 Nov 30.

14.

Targeting BTK through microRNA in chronic lymphocytic leukemia.

Bottoni A, Rizzotto L, Lai TH, Liu C, Smith LL, Mantel R, Reiff S, El-Gamal D, Larkin K, Johnson AJ, Lapalombella R, Lehman A, Plunkett W, Byrd JC, Blachly JS, Woyach JA, Sampath D.

Blood. 2016 Dec 29;128(26):3101-3112. doi: 10.1182/blood-2016-07-727750. Epub 2016 Oct 17.

15.

ATM function and its relationship with ATM gene mutations in chronic lymphocytic leukemia with the recurrent deletion (11q22.3-23.2).

Jiang Y, Chen HC, Su X, Thompson PA, Liu X, Do KA, Wierda W, Keating MJ, Plunkett W.

Blood Cancer J. 2016 Sep 2;6(9):e465. doi: 10.1038/bcj.2016.69.

16.

Mechanism-Based Drug Combinations with the DNA Strand-Breaking Nucleoside Analog CNDAC.

Liu X, Jiang Y, Nowak B, Hargis S, Plunkett W.

Mol Cancer Ther. 2016 Oct;15(10):2302-2313. Epub 2016 Jul 29.

17.

Derivatization of agelastatin A leading to bioactive analogs and a trifunctional probe.

Jouanneau M, McClary B, Reyes JC, Chen R, Chen Y, Plunkett W, Cheng X, Milinichik AZ, Albone EF, Liu JO, Romo D.

Bioorg Med Chem Lett. 2016 Apr 15;26(8):2092-7. doi: 10.1016/j.bmcl.2016.02.051. Epub 2016 Feb 23.

18.

HDAC Inhibition Induces MicroRNA-182, which Targets RAD51 and Impairs HR Repair to Sensitize Cells to Sapacitabine in Acute Myelogenous Leukemia.

Lai TH, Ewald B, Zecevic A, Liu C, Sulda M, Papaioannou D, Garzon R, Blachly JS, Plunkett W, Sampath D.

Clin Cancer Res. 2016 Jul 15;22(14):3537-49. doi: 10.1158/1078-0432.CCR-15-1063. Epub 2016 Feb 8.

19.

Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia.

Thompson PA, Tam CS, O'Brien SM, Wierda WG, Stingo F, Plunkett W, Smith SC, Kantarjian HM, Freireich EJ, Keating MJ.

Blood. 2016 Jan 21;127(3):303-9. doi: 10.1182/blood-2015-09-667675. Epub 2015 Oct 22.

20.

Arginine addiction in AML.

Plunkett W.

Blood. 2015 Jun 25;125(26):3971-2. doi: 10.1182/blood-2015-05-643411.

PMID:
26113532
21.

Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia.

Yeh YY, Chen R, Hessler J, Mahoney E, Lehman AM, Heerema NA, Grever MR, Plunkett W, Byrd JC, Johnson AJ.

Oncotarget. 2015 Feb 20;6(5):2667-79.

22.

Intra-tumoral heterogeneity of gemcitabine delivery and mass transport in human pancreatic cancer.

Koay EJ, Baio FE, Ondari A, Truty MJ, Cristini V, Thomas RM, Chen R, Chatterjee D, Kang Y, Zhang J, Court L, Bhosale PR, Tamm EP, Qayyum A, Crane CH, Javle M, Katz MH, Gottumukkala VN, Rozner MA, Shen H, Lee JE, Wang H, Chen Y, Plunkett W, Abbruzzese JL, Wolff RA, Maitra A, Ferrari M, Varadhachary GR, Fleming JB.

Phys Biol. 2014 Nov 26;11(6):065002. doi: 10.1088/1478-3975/11/6/065002.

23.

Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab).

Tam CS, O'Brien S, Plunkett W, Wierda W, Ferrajoli A, Wang X, Do KA, Cortes J, Khouri I, Kantarjian H, Lerner S, Keating MJ.

Blood. 2014 Nov 13;124(20):3059-64. doi: 10.1182/blood-2014-06-583765. Epub 2014 Oct 3.

24.

A phase I study of fludarabine, cytarabine, and oxaliplatin therapy in patients with relapsed or refractory acute myeloid leukemia.

Tsimberidou AM, Keating MJ, Jabbour EJ, Ravandi-Kashani F, O'Brien S, Estey E, Bekele N, Plunkett WK Jr, Kantarjian H, Borthakur G.

Clin Lymphoma Myeloma Leuk. 2014 Oct;14(5):395-400.e1. doi: 10.1016/j.clml.2014.01.009. Epub 2014 Feb 3.

25.

Transport properties of pancreatic cancer describe gemcitabine delivery and response.

Koay EJ, Truty MJ, Cristini V, Thomas RM, Chen R, Chatterjee D, Kang Y, Bhosale PR, Tamm EP, Crane CH, Javle M, Katz MH, Gottumukkala VN, Rozner MA, Shen H, Lee JE, Wang H, Chen Y, Plunkett W, Abbruzzese JL, Wolff RA, Varadhachary GR, Ferrari M, Fleming JB.

J Clin Invest. 2014 Apr;124(4):1525-36. doi: 10.1172/JCI73455. Epub 2014 Mar 10.

26.

Omacetaxine: a protein translation inhibitor for treatment of chronic myelogenous leukemia.

Gandhi V, Plunkett W, Cortes JE.

Clin Cancer Res. 2014 Apr 1;20(7):1735-40. doi: 10.1158/1078-0432.CCR-13-1283. Epub 2014 Feb 5.

27.

Phase I and extension study of clofarabine plus cyclophosphamide in patients with relapsed/refractory acute lymphoblastic leukemia.

Faderl S, Balakrishnan K, Thomas DA, Ravandi F, Borthakur G, Burger J, Ferrajoli A, Cortes J, O'Brien S, Kadia T, Feliu J, Plunkett W, Gandhi V, Kantarjian HM.

Clin Lymphoma Myeloma Leuk. 2014 Jun;14(3):231-8. doi: 10.1016/j.clml.2013.12.001. Epub 2013 Dec 17.

28.

Molecular recognition of aliphatic diamines by 3,3'-di(trifluoroacetyl)-1,1'-bi-2-naphthol.

Yu S, Plunkett W, Kim M, Wu E, Sabat M, Pu L.

J Org Chem. 2013 Dec 20;78(24):12671-80. doi: 10.1021/jo402277p. Epub 2013 Dec 6.

PMID:
24283254
29.

RRM1 and RRM2 pharmacogenetics: association with phenotypes in HapMap cell lines and acute myeloid leukemia patients.

Cao X, Mitra AK, Pounds S, Crews KR, Gandhi V, Plunkett W, Dolan ME, Hartford C, Raimondi S, Campana D, Downing J, Rubnitz JE, Ribeiro RC, Lamba JK.

Pharmacogenomics. 2013 Sep;14(12):1449-66. doi: 10.2217/pgs.13.131.

30.

Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies.

Sampath D, Malik A, Plunkett W, Nowak B, Williams B, Burton M, Verstovsek S, Faderl S, Garcia-Manero G, List AF, Sebti S, Kantarjian HM, Ravandi F, Lancet JE.

Leuk Res. 2013 Nov;37(11):1461-7. doi: 10.1016/j.leukres.2013.07.034. Epub 2013 Aug 6.

31.

Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndrome.

Tsimberidou AM, Wierda WG, Wen S, Plunkett W, O'Brien S, Kipps TJ, Jones JA, Badoux X, Kantarjian H, Keating MJ; Chronic Lymphocytic Leukemia Research Consortium.

Clin Lymphoma Myeloma Leuk. 2013 Oct;13(5):568-74. doi: 10.1016/j.clml.2013.03.012. Epub 2013 Jun 27.

32.

Simultaneous determination of both the enantiomeric composition and concentration of a chiral substrate with one fluorescent sensor.

Yu S, Plunkett W, Kim M, Pu L.

J Am Chem Soc. 2012 Dec 19;134(50):20282-5. doi: 10.1021/ja3101165. Epub 2012 Dec 11.

PMID:
23214478
33.

Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study.

Kantarjian H, Faderl S, Garcia-Manero G, Luger S, Venugopal P, Maness L, Wetzler M, Coutre S, Stock W, Claxton D, Goldberg SL, Arellano M, Strickland SA, Seiter K, Schiller G, Jabbour E, Chiao J, Plunkett W.

Lancet Oncol. 2012 Nov;13(11):1096-104. doi: 10.1016/S1470-2045(12)70436-9. Epub 2012 Oct 15.

34.

Sapacitabine, the prodrug of CNDAC, is a nucleoside analog with a unique action mechanism of inducing DNA strand breaks.

Liu XJ, Nowak B, Wang YQ, Plunkett W.

Chin J Cancer. 2012 Aug;31(8):373-80. doi: 10.5732/cjc.012.10077. Epub 2012 Jun 26.

35.

Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia.

Jabbour E, Garcia-Manero G, Cortes J, Ravandi F, Plunkett W, Gandhi V, Faderl S, O'Brien S, Borthakur G, Kadia T, Burger J, Konopleva M, Brandt M, Huang X, Kantarjian H.

Clin Lymphoma Myeloma Leuk. 2012 Aug;12(4):244-51. doi: 10.1016/j.clml.2012.03.003. Epub 2012 Apr 24.

36.

Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia.

Zhang W, Trachootham D, Liu J, Chen G, Pelicano H, Garcia-Prieto C, Lu W, Burger JA, Croce CM, Plunkett W, Keating MJ, Huang P.

Nat Cell Biol. 2012 Feb 19;14(3):276-86. doi: 10.1038/ncb2432.

37.

Sapacitabine for cancer.

Liu X, Kantarjian H, Plunkett W.

Expert Opin Investig Drugs. 2012 Apr;21(4):541-55. doi: 10.1517/13543784.2012.660249. Epub 2012 Feb 14. Review.

38.

MRx102, a triptolide derivative, has potent antileukemic activity in vitro and in a murine model of AML.

Carter BZ, Mak DH, Shi Y, Fidler JM, Chen R, Ling X, Plunkett W, Andreeff M.

Leukemia. 2012 Mar;26(3):443-50. doi: 10.1038/leu.2011.246. Epub 2011 Sep 9.

39.

Genetic variants in cytosolic 5'-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemia.

Mitra AK, Crews KR, Pounds S, Cao X, Feldberg T, Ghodke Y, Gandhi V, Plunkett W, Dolan ME, Hartford C, Raimondi S, Campana D, Downing J, Rubnitz JE, Ribeiro RC, Lamba JK.

J Pharmacol Exp Ther. 2011 Oct;339(1):9-23. doi: 10.1124/jpet.111.182873. Epub 2011 Jun 28.

40.

Killing of chronic lymphocytic leukemia by the combination of fludarabine and oxaliplatin is dependent on the activity of XPF endonuclease.

Zecevic A, Sampath D, Ewald B, Chen R, Wierda W, Plunkett W.

Clin Cancer Res. 2011 Jul 15;17(14):4731-41. doi: 10.1158/1078-0432.CCR-10-2561. Epub 2011 Jun 1.

41.

DNA-dependent protein kinase and ataxia telangiectasia mutated (ATM) promote cell survival in response to NK314, a topoisomerase IIα inhibitor.

Guo L, Liu X, Jiang Y, Nishikawa K, Plunkett W.

Mol Pharmacol. 2011 Aug;80(2):321-7. doi: 10.1124/mol.109.057125. Epub 2011 May 5.

42.

Identification of predictive markers of cytarabine response in AML by integrative analysis of gene-expression profiles with multiple phenotypes.

Lamba JK, Crews KR, Pounds SB, Cao X, Gandhi V, Plunkett W, Razzouk BI, Lamba V, Baker SD, Raimondi SC, Campana D, Pui CH, Downing JR, Rubnitz JE, Ribeiro RC.

Pharmacogenomics. 2011 Mar;12(3):327-39. doi: 10.2217/pgs.10.191.

43.

TRIM24 links a non-canonical histone signature to breast cancer.

Tsai WW, Wang Z, Yiu TT, Akdemir KC, Xia W, Winter S, Tsai CY, Shi X, Schwarzer D, Plunkett W, Aronow B, Gozani O, Fischle W, Hung MC, Patel DJ, Barton MC.

Nature. 2010 Dec 16;468(7326):927-32. doi: 10.1038/nature09542.

44.

Clofarabine in leukemia.

Ghanem H, Jabbour E, Faderl S, Ghandhi V, Plunkett W, Kantarjian H.

Expert Rev Hematol. 2010 Feb;3(1):15-22. doi: 10.1586/ehm.09.70. Review.

PMID:
21082931
45.

Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia.

Chen R, Guo L, Chen Y, Jiang Y, Wierda WG, Plunkett W.

Blood. 2011 Jan 6;117(1):156-64. doi: 10.1182/blood-2010-01-262808. Epub 2010 Oct 22.

46.

Responses in mantle cell lymphoma cells to SNS-032 depend on the biological context of each cell line.

Chen R, Chubb S, Cheng T, Hawtin RE, Gandhi V, Plunkett W.

Cancer Res. 2010 Aug 15;70(16):6587-97. doi: 10.1158/0008-5472.CAN-09-3578. Epub 2010 Jul 27.

47.

Formation mechanism of silver nanoparticle 1D microstructures and their hierarchical assembly into 3D superstructures.

Suber L, Plunkett WR.

Nanoscale. 2010 Jan;2(1):128-33. doi: 10.1039/b9nr00072k. Epub 2009 Oct 6.

PMID:
20648374
48.

Strategy to induce apoptosis and circumvent resistance in chronic lymphocytic leukaemia.

Chen R, Plunkett W.

Best Pract Res Clin Haematol. 2010 Mar;23(1):155-66. doi: 10.1016/j.beha.2010.01.003. Review.

PMID:
20620979
49.

Thermal hysteresis of Morin transition in hematite particles.

Suber L, Imperatori P, Mari A, Marchegiani G, Mansilla MV, Fiorani D, Plunkett WR, Rinaldi D, Cannas C, Ennas G, Peddis D.

Phys Chem Chem Phys. 2010 Jul 14;12(26):6984-9. doi: 10.1039/b925371h. Epub 2010 May 18.

PMID:
20485727
50.

Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma.

Tong WG, Chen R, Plunkett W, Siegel D, Sinha R, Harvey RD, Badros AZ, Popplewell L, Coutre S, Fox JA, Mahadocon K, Chen T, Kegley P, Hoch U, Wierda WG.

J Clin Oncol. 2010 Jun 20;28(18):3015-22. doi: 10.1200/JCO.2009.26.1347. Epub 2010 May 17.

Supplemental Content

Loading ...
Support Center